Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 407 (1) , 112785
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health
This publication has 34 references indexed in Scilit:
- A Rapid and Sensitive Method for Measuring N-Acetylglucosaminidase Activity in Cultured CellsPLOS ONE, 2013
- Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditionsNature Protocols, 2012
- Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIBPLOS ONE, 2012
- Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cellsHuman Molecular Genetics, 2011
- Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and GreeceAmerican Journal of Medical Genetics Part A, 2010
- Storage Vesicles in Neurons Are Related to Golgi Complex Alterations in Mucopolysaccharidosis IIIBThe American Journal of Pathology, 2010
- Secondary lipid accumulation in lysosomal diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Early Neurodegeneration Progresses Independently of Microglial Activation by Heparan Sulfate in the Brain of Mucopolysaccharidosis IIIB MicePLOS ONE, 2008
- Evaluation of Accumulated Mucopolysaccharides in the Brain of Patients with Mucopolysaccharidoses by 1H-Magnetic Resonance Spectroscopy before and after Bone Marrow TransplantationPediatric Research, 2001
- Nile red: a selective fluorescent stain for intracellular lipid droplets.Journal of Cell Biology, 1985